1. Home
  2. ELTK vs IMMP Comparison

ELTK vs IMMP Comparison

Compare ELTK & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eltek Ltd.

ELTK

Eltek Ltd.

HOLD

Current Price

$9.45

Market Cap

65.0M

Sector

Technology

ML Signal

HOLD

Logo Immutep Limited

IMMP

Immutep Limited

HOLD

Current Price

$0.38

Market Cap

54.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ELTK
IMMP
Founded
1970
1987
Country
Israel
Australia
Employees
N/A
N/A
Industry
Electrical Products
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
65.0M
54.4M
IPO Year
1998
2012

Fundamental Metrics

Financial Performance
Metric
ELTK
IMMP
Price
$9.45
$0.38
Analyst Decision
Hold
Analyst Count
0
3
Target Price
N/A
$5.50
AVG Volume (30 Days)
9.7K
605.0K
Earning Date
05-19-2026
05-12-2026
Dividend Yield
2.14%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$16.18
$445.09
Revenue Next Year
N/A
N/A
P/E Ratio
$48.71
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.30
$0.29
52 Week High
$12.19
$3.53

Technical Indicators

Market Signals
Indicator
ELTK
IMMP
Relative Strength Index (RSI) 56.45 38.68
Support Level $8.05 $0.35
Resistance Level $11.52 $0.39
Average True Range (ATR) 0.66 0.02
MACD 0.01 0.01
Stochastic Oscillator 32.62 29.98

Price Performance

Historical Comparison
ELTK
IMMP

About ELTK Eltek Ltd.

Eltek Ltd is engaged in the technology business sector that manufactures and supplies technologically new custom-made circuitry solutions. The company manufactures, markets, and sells custom-made printed circuit boards (PCBs), including high-density interconnect, flex-rigid and multi-layered boards. The Company markets its products mainly to the medical technology, defense and aerospace, industrial, telecom, and networking equipment industries. The geographic areas of the company are Israel, North America, the Netherlands, India, and Others. It generates the majority of its revenue from Israel.

About IMMP Immutep Limited

Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

Share on Social Networks: